Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
RayzeBio, Inc. | 10%+ Owner | Common Stock | 1,857,706 | $116 M | $62.50 | Sep 19, 2023 | Indirect |
Shattuck Labs, Inc. | Director, 10%+ Owner | Common Stock | 5,615,489 | $59.1 M | $10.53 | Mar 28, 2024 | Indirect |
FATE THERAPEUTICS INC | Director, 10%+ Owner | Common Stock | 13,180,388 | $57.6 M | $4.37 | Dec 26, 2023 | Indirect |
IGM Biosciences, Inc. | Director, 10%+ Owner | Non-Voting Common Stock | 7,199,325 | $47.5 M | $6.60 | Feb 28, 2024 | Indirect |
ADC Therapeutics SA | 10%+ Owner | Common Shares, par value CHF 0.08 per share | 15,669,217 | $44 M | $2.81 | Jul 1, 2024 | Indirect |
Absci Corp | Director | Common Stock | 8,262,136 | $41.1 M | $4.98 | Jun 12, 2024 | Indirect |
ADC Therapeutics SA | 10%+ Owner | Pre-Funded Warrants | 8,163,265 | $39.3 M | $4.81 | May 8, 2024 | Indirect |
ADC Therapeutics SA | 10%+ Owner | Common Shares, par value CHF 0.08 per share | 12,995,040 | $36.5 M | $2.81 | Jul 1, 2024 | Direct |
Entrada Therapeutics, Inc. | 10%+ Owner | Common Stock | 1,954,420 | $31.3 M | $15.99 | Nov 2, 2021 | Indirect |
Zymeworks Inc. | 10%+ Owner | Common Stock, par value $0.00001 per share | 6,075,918 | $30.6 M | $5.03 | Oct 13, 2022 | Indirect |
ADC Therapeutics SA | 10%+ Owner | Pre-Funded Warrants | 6,107,181 | $29.4 M | $4.81 | May 8, 2024 | Direct |
IGM Biosciences, Inc. | Director, 10%+ Owner | Common Stock | 3,080,066 | $23.3 M | $7.58 | Jun 28, 2024 | Indirect |
FATE THERAPEUTICS INC | Director, 10%+ Owner | Pre-Funded Warrants to Purchase Common Stock | 3,893,674 | $21.4 M | $5.50 | Mar 21, 2024 | Indirect |
Augmedix, Inc. | Director, 10%+ Owner | Common Stock | 16,421,788 | $19.5 M | $1.19 | Jun 14, 2024 | Indirect |
Verve Therapeutics, Inc. | 10%+ Owner | Common Stock | 1,936,530 | $19.4 M | $10.00 | Jun 21, 2021 | Indirect |
Adagio Therapeutics, Inc. | 10%+ Owner | Common Stock | 3,390,960 | $13.4 M | $3.95 | Aug 10, 2021 | Indirect |
ADC Therapeutics SA | 10%+ Owner | Cash-settled Swaps | 107,590 | $364 K | $3.38 | Feb 7, 2024 | Direct |
FATE THERAPEUTICS INC | Director, 10%+ Owner | Stock Option (Right to Buy) | 40,000 | $109 K | $2.73 | Jun 7, 2024 | Indirect |
ADC Therapeutics SA | 10%+ Owner | Cash-settled Swaps | 11,159 | $37.8 K | $3.38 | Feb 2, 2024 | Indirect |
Science 37 Holdings, Inc. | Former 10% Owner and Director | Common Stock | 0 | $0 | $5.75 | Mar 12, 2024 | Indirect |
MedAvail Holdings, Inc. | Director, 10%+ Owner | Series A Warrants to Purchase Common Stock | 38,916,562 | Jun 16, 2023 | Direct | ||
MedAvail Holdings, Inc. | Director, 10%+ Owner | Series A Warrants to Purchase Common Stock | 38,916,562 | Jun 16, 2023 | Indirect | ||
Shattuck Labs, Inc. | Director, 10%+ Owner | Pre-Funded Warrant to Purchase Common Stock | 3,100,823 | Dec 21, 2023 | Indirect | ||
Augmedix, Inc. | Director, 10%+ Owner | Breakeven Warrant | 1,093,799 | Nov 20, 2023 | Direct | ||
Augmedix, Inc. | Director, 10%+ Owner | Breakeven Warrant | 1,093,799 | Nov 20, 2023 | Indirect | ||
Absci Corp | Director | Stock Option (Right to Buy) | 36,274 | Jun 12, 2024 | Indirect | ||
IGM Biosciences, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 29,400 | Mar 12, 2024 | Indirect | ||
Shattuck Labs, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 27,700 | Jun 21, 2024 | Indirect | ||
Adagio Therapeutics, Inc. | 10%+ Owner | Series C Preferred Stock | 0 | Aug 10, 2021 | Indirect | ||
Entrada Therapeutics, Inc. | 10%+ Owner | Series B Convertible Preferred Stock | 0 | Nov 2, 2021 | Indirect | ||
RayzeBio, Inc. | 10%+ Owner | Series B Preferred Stock | 0 | Sep 19, 2023 | Indirect | ||
RayzeBio, Inc. | 10%+ Owner | Series C Preferred Stock | 0 | Sep 19, 2023 | Indirect | ||
RayzeBio, Inc. | 10%+ Owner | Series D Preferred Stock | 0 | Sep 19, 2023 | Indirect | ||
Science 37 Holdings, Inc. | Former 10% Owner and Director | Earn-Out Right | 0 | Mar 12, 2024 | Indirect | ||
Science 37 Holdings, Inc. | Former 10% Owner and Director | Stock Options (Right to Buy) | 0 | Mar 12, 2024 | Indirect | ||
Verve Therapeutics, Inc. | 10%+ Owner | Series B Convertible Preferred Stock | 0 | Jun 21, 2021 | Indirect |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ADCT | ADC Therapeutics SA | Jul 1, 2024 | 2 | 2,248,000 | 4 | Jul 3, 2024 | 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Jun 28, 2024 | 1 | 0 | 4 | Jul 2, 2024 | Director, 10%+ Owner |
STTK | Shattuck Labs, Inc. | Jun 21, 2024 | 1 | 0 | 4 | Jun 21, 2024 | Director, 10%+ Owner |
AUGX | Augmedix, Inc. | Jun 14, 2024 | 1 | 0 | 4 | Jun 18, 2024 | Director, 10%+ Owner |
ABSI | Absci Corp | Jun 12, 2024 | 2 | 0 | 4 | Jun 14, 2024 | Director |
FATE | FATE THERAPEUTICS INC | Jun 7, 2024 | 1 | 0 | 4 | Jun 11, 2024 | Director, 10%+ Owner |
ADCT | ADC Therapeutics SA | May 8, 2024 | 2 | 68,669,386 | 4 | May 10, 2024 | 10%+ Owner |
STTK | Shattuck Labs, Inc. | Mar 28, 2024 | 1 | 0 | 4 | Apr 1, 2024 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Mar 28, 2024 | 2 | 0 | 4 | Apr 1, 2024 | Director, 10%+ Owner |
FATE | FATE THERAPEUTICS INC | Mar 21, 2024 | 1 | 19,996,366 | 4 | Mar 25, 2024 | Director, 10%+ Owner |
AUGX | Augmedix, Inc. | Mar 15, 2024 | 1 | 0 | 4 | Mar 19, 2024 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Mar 12, 2024 | 1 | 0 | 4 | Mar 14, 2024 | Director, 10%+ Owner |
SNCE | Science 37 Holdings, Inc. | Mar 12, 2024 | 3 | -5,848,917 | 4 | Mar 13, 2024 | Former 10% Owner and Director |
ABSI | Absci Corp | Mar 1, 2024 | 1 | 999,999 | 4 | Mar 5, 2024 | Director |
IGMS | IGM Biosciences, Inc. | Feb 28, 2024 | 2 | 0 | 4 | Mar 1, 2024 | Director, 10%+ Owner |
ADCT | ADC Therapeutics SA | Jan 3, 2024 | 22 | -167,175 | 4 | Feb 9, 2024 | 10%+ Owner |
ADCT | ADC Therapeutics SA | Jan 2, 2024 | 0 | 0 | 3 | Feb 9, 2024 | 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Dec 29, 2023 | 1 | 0 | 4 | Jan 3, 2024 | Director |
FATE | FATE THERAPEUTICS INC | Dec 26, 2023 | 3 | 166,024 | 4 | Dec 28, 2023 | Director, 10%+ Owner |
STTK | Shattuck Labs, Inc. | Dec 21, 2023 | 1 | 0 | 4 | Dec 26, 2023 | Director, 10%+ Owner |
AUGX | Augmedix, Inc. | Dec 15, 2023 | 1 | 0 | 4 | Dec 19, 2023 | Director, 10%+ Owner |
AUGX | Augmedix, Inc. | Nov 20, 2023 | 4 | 6,000,000 | 4 | Nov 22, 2023 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Sep 29, 2023 | 1 | 0 | 4 | Oct 3, 2023 | Director |
RYZB | RayzeBio, Inc. | Sep 19, 2023 | 6 | 0 | 4 | Sep 21, 2023 | 10%+ Owner |
RYZB | RayzeBio, Inc. | Sep 14, 2023 | 0 | 0 | 3 | Sep 14, 2023 | 10%+ Owner |
AUGX | Augmedix, Inc. | Aug 31, 2023 | 1 | 10,000 | 4 | Sep 5, 2023 | Director, 10%+ Owner |
AUGX | Augmedix, Inc. | Jul 13, 2023 | 1 | 0 | 4 | Jul 17, 2023 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Jun 29, 2023 | 5 | 0 | 4 | Jul 3, 2023 | Director |
IGMS | IGM Biosciences, Inc. | Jun 26, 2023 | 1 | 22,500,000 | 4 | Jun 28, 2023 | Director |
MDVL | MedAvail Holdings, Inc. | Jun 16, 2023 | 2 | 0 | 4 | Jun 21, 2023 | Director, 10%+ Owner |
ABSI | Absci Corp | Jun 14, 2023 | 1 | 0 | 4 | Jun 16, 2023 | Director |
FATE | FATE THERAPEUTICS INC | Jun 6, 2023 | 1 | 0 | 4 | Jun 8, 2023 | Director, 10%+ Owner |
STTK | Shattuck Labs, Inc. | May 26, 2023 | 1 | 0 | 4 | May 31, 2023 | Director, 10%+ Owner |
SNCE | Science 37 Holdings, Inc. | May 11, 2023 | 1 | 125,000 | 4 | May 15, 2023 | Director, 10%+ Owner |
AUGX | Augmedix, Inc. | May 2, 2023 | 3 | -15,000,000 | 4 | May 4, 2023 | Director, 10%+ Owner |
FATE | FATE THERAPEUTICS INC | Apr 20, 2023 | 2 | 1,705,829 | 4 | Apr 21, 2023 | Director, 10%+ Owner |
AUGX | Augmedix, Inc. | Apr 19, 2023 | 2 | 6,999,999 | 4 | Apr 21, 2023 | Director, 10%+ Owner |
FATE | FATE THERAPEUTICS INC | Apr 13, 2023 | 12 | -1,611,460 | 4 | Apr 17, 2023 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Apr 4, 2023 | 1 | 0 | 4 | Apr 6, 2023 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Mar 31, 2023 | 1 | 0 | 4 | Apr 4, 2023 | Director, 10%+ Owner |
MDVL | MedAvail Holdings, Inc. | Mar 9, 2023 | 2 | 24,999,999 | 4 | Mar 13, 2023 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Dec 30, 2022 | 1 | 0 | 4 | Jan 4, 2023 | Director, 10%+ Owner |
ZYME | Zymeworks Inc. | Oct 13, 2022 | 1 | 153,435 | 4/A | Oct 18, 2022 | 10%+ Owner |
ZYME | Zymeworks Inc. | Oct 13, 2022 | 0 | 0 | 3 | Oct 17, 2022 | 10%+ Owner |
ZYME | Zymeworks Inc. | Oct 13, 2022 | 0 | 0 | 3 | Oct 17, 2022 | 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Oct 3, 2022 | 6 | 0 | 4 | Oct 5, 2022 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Sep 30, 2022 | 1 | 0 | 4 | Oct 4, 2022 | Director, 10%+ Owner |
MDVL | MedAvail Holdings, Inc. | Jul 1, 2022 | 4 | 18,116,562 | 4 | Jul 6, 2022 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Jun 30, 2022 | 1 | 0 | 4 | Jul 5, 2022 | Director, 10%+ Owner |
SNCE | Science 37 Holdings, Inc. | Jun 13, 2022 | 2 | 0 | 4 | Jun 15, 2022 | Director, 10%+ Owner |
FATE | FATE THERAPEUTICS INC | Jun 9, 2022 | 2 | 0 | 4 | Jun 13, 2022 | Director, 10%+ Owner |
STTK | Shattuck Labs, Inc. | Jun 8, 2022 | 1 | 0 | 4 | Jun 10, 2022 | Director, 10%+ Owner |
ABSI | Absci Corp | Jun 8, 2022 | 1 | 0 | 4 | Jun 10, 2022 | Director, 10%+ Owner |
SNCE | Science 37 Holdings, Inc. | May 23, 2022 | 1 | 124,998 | 4 | May 25, 2022 | Director, 10%+ Owner |
MDVL | MedAvail Holdings, Inc. | Apr 4, 2022 | 2 | 14,999,999 | 4 | Apr 6, 2022 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Mar 31, 2022 | 2 | 59,999,985 | 4 | Apr 4, 2022 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Mar 12, 2022 | 1 | 0 | 4 | Mar 15, 2022 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Dec 31, 2021 | 1 | 0 | 4 | Jan 4, 2022 | Director, 10%+ Owner |
TRDA | Entrada Therapeutics, Inc. | Nov 2, 2021 | 3 | 20,000,000 | 4 | Nov 4, 2021 | 10%+ Owner |
AUGX | Augmedix, Inc. | Oct 28, 2021 | 1 | 6,500,000 | 4/A | Apr 21, 2023 | Director, 10%+ Owner |
TRDA | Entrada Therapeutics, Inc. | Oct 28, 2021 | 0 | 0 | 3 | Oct 28, 2021 | 10%+ Owner |
SNCE | Science 37 Holdings, Inc. | Oct 7, 2021 | 1 | 0 | 4 | Oct 12, 2021 | Director, 10%+ Owner |
SNCE | Science 37 Holdings, Inc. | Oct 6, 2021 | 1 | 0 | 4/A | Oct 18, 2021 | Director, 10%+ Owner |
SNCE | Science 37 Holdings, Inc. | Oct 6, 2021 | 0 | 0 | 3 | Oct 8, 2021 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Sep 30, 2021 | 1 | 0 | 4 | Oct 4, 2021 | Director, 10%+ Owner |
IVVD | Adagio Therapeutics, Inc. | Aug 10, 2021 | 3 | 24,990,000 | 4 | Aug 12, 2021 | 10%+ Owner |
IVVD | Adagio Therapeutics, Inc. | Aug 5, 2021 | 0 | 0 | 3 | Aug 5, 2021 | 10%+ Owner |
ABSI | Absci Corp | Jul 26, 2021 | 5 | 5,000,000 | 4 | Jul 28, 2021 | Director |
ABSI | Absci Corp | Jul 21, 2021 | 0 | 0 | 3 | Jul 21, 2021 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Jun 30, 2021 | 1 | 0 | 4 | Jul 2, 2021 | Director, 10%+ Owner |
VERV | Verve Therapeutics, Inc. | Jun 21, 2021 | 3 | 19,950,000 | 4 | Jun 23, 2021 | 10%+ Owner |
STTK | Shattuck Labs, Inc. | Jun 19, 2021 | 1 | 0 | 4 | Jun 22, 2021 | Director, 10%+ Owner |
VERV | Verve Therapeutics, Inc. | Jun 16, 2021 | 0 | 0 | 3 | Jun 16, 2021 | 10%+ Owner |
FATE | FATE THERAPEUTICS INC | Jun 2, 2021 | 2 | 0 | 4 | Jun 4, 2021 | Director, 10%+ Owner |